Pertussis, caused by the bacterium whooping‑cough pathogen, is prevented by vaccines that have evolved from early wP formulations to modern aP products such as diphtheria‑tetanus‑acellular pertussis and the booster tetanus‑diptheria‑acellular pertussis. These vaccines are a core component of national immunisation programmes overseen by organisations like the WHO and the CDC, and they are frequently incorporated into pentavalent schedules. While the whole‑cell vaccines pioneered a dramatic fall in disease incidence in the mid‑20th century, their higher adverse‑reaction profile spurred the development of acellular vaccines, which offer improved safety but exhibit waning immunity and challenges in reducing bacterial colonisation. Contemporary strategies therefore emphasize timely Tdap boosters for adolescents, adults and pregnant individuals to sustain population‑level protection and to confer passive antibodies to newborns via pregnancy vaccination. Ongoing research addresses key issues such as the evolution of pertactin‑deficient strains, the need for durable cellular and humoral responses, and the development of next‑generation platforms that target secretory IgA and tissue‑resident memory cells. Understanding the historical milestones, current recommendations, safety considerations and future directions is essential for clinicians, policymakers and the public alike. [1] [2] [3]

History and Global Adoption of Pertussis Vaccines

The fight against whooping cough began in the early 20th century when the French microbiologist Gengou announced the first pertussis vaccine in 1912, and the United States granted the first licensure for a whole‑cell pertussis vaccine in 1914[3]. A major breakthrough came in the 1930s when pediatrician Leila Denmark helped develop the first effective whole‑cell formulation, which, despite its higher reactogenicity, dramatically reduced disease incidence after widespread rollout[5].

Expansion of Whole‑Cell Vaccines (1940s–1970s)

Throughout the 1940s whole‑cell pertussis vaccines (wP) were introduced across many developed nations, forming the backbone of national immunisation programmes. Their deployment coincided with a sharp decline in pertussis cases, hospitalisations and mortality, establishing a new era of public‑health impact[6]. The broad antigenic content of wP vaccines conferred robust, long‑lasting immunity but also generated notable adverse‑reaction profiles, prompting ongoing refinement of formulation and schedule.

Transition to Acellular Vaccines (Late 20th century)

In the late 20th century, the development of acellular pertussis (aP) formulations represented a major milestone. By focusing on purified antigens such as pertussis toxin, filamentous haemagglutinin and pertactin, aP vaccines achieved comparable protection against disease while markedly reducing common side effects[6]. The shift to aP vaccines was rapidly adopted in many high‑income countries, improving public acceptance and facilitating higher coverage rates.

Integration into Combination and Pentavalent Formulations

To simplify delivery and increase uptake, pertussis antigens were incorporated into combination products. The DTaP vaccine merged diphtheria, tetanus and acellular pertussis antigens, while later pentavalent formulations added hepatitis B and Haemophilus influenzae type b components. This strategy reduced the number of injections required per visit and streamlined logistics, further expanding global coverage[8].

Booster Strategies and Maternal Immunisation

Recognising that immunity wanes over time, many countries introduced adolescent and adult Tdap booster programmes to sustain population‑level protection. Maternal immunisation programmes, recommended during each pregnancy, were added to protect newborns through transplacental antibody transfer, a strategy endorsed by the WHO and the CDC[9]. These boosters have become a cornerstone of contemporary pertussis policy.

Recent Advances and Ongoing Challenges

Current research seeks to overcome the limitations of existing aP vaccines, targeting antigens such as pertussis toxin to develop formulations with longer‑lasting immunity and better control of bacterial colonisation[10]. Despite the cumulative successes—dramatic reductions in pertussis cases, hospitalisations and deaths, especially among infants—outbreaks linked to waning immunity and vaccine hesitancy persist, underscoring the need for sustained high coverage and continued vaccine innovation[11].

Whole‑Cell vs. Acellular Vaccines: Composition, Efficacy and Reactogenicity

The two principal formulations used worldwide to prevent whooping cough differ markedly in their make‑up, immune‑stimulating properties, and safety profiles.

Composition and Mechanism of Action

  • Whole‑cell pertussis vaccines (wP) contain killed Bordetella pertussis bacteria, preserving the full complement of bacterial structures, including lipopolysaccharide (LPS) and a broad array of proteins. This complex antigenic landscape facilitates extensive uptake by antigen‑presenting cells (APCs) and drives a strong Th1‑polarised cellular response, which supports long‑lasting memory T‑cell populations [12].
  • Acellular pertussis vaccines (aP) are composed of a limited set of purified components—most commonly pertussis toxin (PT), filamentous haemagglutinin (FHA), pertactin (Prn), and fimbriae. The narrowed antigen repertoire focuses the immune response on these specific proteins, producing a predominantly Th2‑skewed humoral response with high antibody titres but a comparatively weaker cellular arm [13].

Efficacy Profiles

  • Initial protection: Whole‑cell vaccines have demonstrated a higher early effectiveness, preventing roughly 78 % of pertussis disease cases [5].
  • Acellular vaccines achieve variable effectiveness ranging from 71 % to 85 % in routine use, with some systematic reviews reporting initial clinical effectiveness as high as 97–100 % shortly after the primary series, though this protection declines more rapidly over time [15].
  • Durability: Studies consistently show that whole‑cell formulations confer more sustained immunity, maintaining protective cellular responses for longer periods compared with acellular products, which experience a marked waning of protection several years after vaccination [16]. This difference underlies the greater reliance on adolescent and adult Tdap boosters when acellular vaccines are used in infant schedules.

Reactogenicity and Safety

  • Whole‑cell vaccines are associated with higher rates of adverse reactions. Commonly reported events include pronounced local redness and swelling, fever, febrile seizures, and prolonged crying in infants. Rare but serious neurological complications were historically linked to early whole‑cell products, contributing to public concern and the eventual shift toward acellular formulations [17].
  • Acellular vaccines display a markedly lower reactogenicity profile. Typical side effects are mild and self‑limiting: brief injection‑site pain or swelling, low‑grade fever, and transient fussiness. Severe adverse events, such as anaphylaxis, are exceedingly rare for both vaccine types [18]. The reduced inflammatory cytokine milieu associated with the Th2‑biased response of aP vaccines contributes to this improved tolerability [19].

Clinical Implications

  • Safety versus durability trade‑off: The choice between wP and aP vaccines often reflects a balance between the superior short‑term efficacy and tolerability of acellular products and the longer‑lasting, broader immunity conferred by whole‑cell vaccines. In high‑income settings, the lower reactogenicity of aP vaccines has driven their predominant use, while many low‑resource countries continue to employ wP formulations because of cost‑effectiveness and the durability advantage [20].
  • Booster strategies: Because acellular immunity wanes more quickly, immunisation programs that rely on aP vaccines incorporate routine Tdap boosters for adolescents, adults, and pregnant individuals to sustain herd immunity and protect newborns via maternal antibody transfer [21]. Whole‑cell schedules may require fewer boosters but still benefit from adolescent and adult doses to close any residual immunity gaps.

Overall, the dichotomy between whole‑cell and acellular pertussis vaccines reflects fundamental differences in antigen breadth, immune polarisation, and safety. Understanding these distinctions informs public‑health decisions on vaccine selection, booster timing, and future efforts to develop next‑generation formulations that aim to combine the robust, long‑lasting protection of whole‑cell vaccines with the favourable safety profile of acellular products.

Immunological Mechanisms and Duration of Protection

Pertussis vaccines stimulate protection through two complementary arms of the immune system: humoral immunity, mediated by antigen‑specific antibodies, and cellular immunity, driven by T‑cell subsets that orchestrate long‑term memory. The nature of the antigenic stimulus—whole‑cell versus acellular—determines which pathways dominate and consequently influences the duration of protection.

Antigen presentation and T‑cell polarization

  • Whole‑cell (wP) vaccines contain inactivated Bordetella pertussis bacteria, presenting a broad array of bacterial components, including lipopolysaccharide (LPS) and multiple proteins. This complex antigenic milieu is efficiently taken up by antigen‑presenting cells such as dendritic cells, leading to robust activation of Th1‑polarized CD4⁺ T cells. Th1 cells secrete interferon‑γ (IFN‑γ) and promote macrophage activation, generating a durable cellular memory that can persist for years [12].

  • Acellular (aP) vaccines contain purified proteins—pertussis toxin, filamentous haemagglutinin, pertactin, and fimbriae—so antigen presentation is focused on these defined components. This drives a Th2‑skewed response characterized by high levels of IgG4 antibodies and relatively weaker IFN‑γ production [13]. The resulting immunity is strong in the short term but establishes less extensive memory T‑cell pools, contributing to faster waning of protection.

Humoral versus cellular correlates of protection

Both vaccine types elicit neutralizing antibodies that block the binding of pertussis toxin and prevent bacterial adhesion. However, the quality of the antibody response differs:

  • wP vaccines generate a broader antibody repertoire, including antibodies that recognize multiple surface antigens, which correlates with more sustained opsonophagocytic activity.
  • aP vaccines produce high titers against the included antigens, giving excellent early protection (up to 97 % effectiveness shortly after the primary series) but with a marked decline in antibody levels over 5–10 years [15].

The cellular component—particularly Th1 and Th17 cells—is critical for clearing Bordetella pertussis from the respiratory mucosa. Studies of individuals vaccinated with wP have identified long‑lived tissue‑resident memory CD4⁺ T cells in the lungs that produce IFN‑γ and IL‑17 upon re‑exposure, providing rapid local immunity [25]. In contrast, aP‑vaccinated subjects exhibit fewer of these resident memory cells, which helps explain the reduced durability of protection.

Mucosal immunity and transmission control

Systemic antibodies limit severe disease but do not fully prevent colonisation of the upper respiratory tract, the primary site of B. pertussis infection. Secretory IgA (sIgA) at mucosal surfaces can neutralise bacteria before they attach to epithelial cells, a mechanism more effectively induced by mucosal delivery (e.g., intranasal) rather than intramuscular injection. Experimental models using mucosal administration of DTaP have demonstrated induction of sIgA, reduction of bacterial load, and blockage of transmission [10]. Conventional injectable aP vaccines generate limited sIgA, which is a key reason they reduce disease severity but only modestly affect transmission.

Duration of protection and waning immunity

The durability of immunity reflects the balance between antibody decay and memory cell maintenance:

  • Whole‑cell formulations provide more sustained cellular memory, resulting in slower decline of protective efficacy over time. Long‑term epidemiological data from the 1940s onward show that wP‑induced immunity can protect for many years, reducing both disease incidence and transmission [6].

  • Acellular formulations achieve high initial efficacy but experience significant waning. Clinical effectiveness drops from near‑100 % shortly after the series to below 70 % within a decade, leading to increased susceptibility in adolescents and adults and prompting the need for Tdap booster doses [21].

This waning underlies the resurgence of pertussis in older age groups and drives current policies that emphasize timely boosters for adolescents, pregnant people, and adults to sustain herd immunity.

Implications for next‑generation vaccine design

Understanding that broad antigen exposure (as in wP) yields durable Th1/Th17 memory whereas narrow antigenic focus (as in aP) favours a rapid but transient Th2 response informs the development of new platforms:

  • Novel adjuvants (e.g., TLR2 agonists derived from B. pertussis) aim to replicate the strong innate activation of wP while preserving the safety of aP [29].
  • Mucosal delivery systems (e.g., intranasal vectors or liposome‑based formulations) seek to generate local sIgA and tissue‑resident memory cells, targeting the site of bacterial entry and improving sterilizing immunity [30].

By combining a broader antigenic spectrum, potent adjuvant signaling, and mucosal immunisation, next‑generation pertussis vaccines aim to achieve lifelong protection and curtail transmission more effectively than current acellular products.

Key internal links: whooping‑cough pathogen, antigen‑presenting cell, dendritic cell, Th1 immune response, Th2 immune response, interferon‑gamma, interleukin‑17, memory B cell, memory T cell, tissue‑resident memory T cell, secretory IgA, intranasal vaccine, adjuvant, TLR2 agonist, Tdap booster, herd immunity.

Recommended Immunisation Schedules and Booster Strategies

Pertussis immunisation begins in infancy with a primary series of diphtheria‑tetanus‑acellular pertussis (DTaP) administered at 2 months, 4 months, 6 months, 15–18 months, and again at 4–6 years of age. This schedule establishes the foundation of protective immunity during the period of greatest vulnerability to severe disease [21][32].

Adolescent and Adult Boosters

Protection from the primary series wanes several years after the last dose, creating a susceptibility gap in early adolescence. Consequently, a single dose of tetanus‑diptheria‑acellular pertussis (Tdap) is recommended for all adolescents at age 11 or 12 years, regardless of the interval since the previous tetanus‑containing vaccine [21][34]. This booster re‑stimulates immunity and reduces the risk of transmission to younger, unprotected contacts.

For adults who have never received Tdap, a single dose is advised, with additional doses every 10 years for those at continued risk (e.g., healthcare workers, caregivers of infants) [21].

Maternal Immunisation

Pregnant individuals receive a Tdap dose during each pregnancy, ideally between 27 and 36 weeks gestation, to generate high maternal antibody titres that cross the placenta and provide passive protection to newborns during the first 2–3 months of life [21][37].

Global Guidance and Booster Timing

The WHO recommends additional booster doses later in life based on local epidemiology, aiming to sustain herd immunity and curb outbreaks [9]. Countries such as Canada have implemented adolescent and adult booster programs to address waning immunity and reduce transmission [39].

Rationale for Booster Strategies

Booster doses counteract the natural decline in antibody levels and T‑cell memory observed after the primary DTaP series. Studies show that waning immunity contributes to increased susceptibility in older children, adolescents, and adults, which in turn facilitates transmission to vulnerable infants [40]. By maintaining a high proportion of immune individuals, boosters lower the overall number of susceptible hosts, thereby reducing the basic reproduction number (R₀) and preventing community‑wide outbreaks [41][42].

Impact of Waning Immunity on Public‑Health Outcomes

Longitudinal surveillance demonstrates that protection from the primary series declines markedly within 5–10 years, coinciding with the age range when adolescents begin schooling and have increased social contact. This period aligns with documented spikes in pertussis incidence, underscoring the need for timely Tdap boosters [15]. Failure to administer boosters can lead to outbreaks even in countries with historically high vaccine coverage.

Future Directions

Emerging evidence highlights the importance of booster timing to maximize both individual protection and herd immunity. Ongoing research into next‑generation vaccines seeks to extend the durability of immunity, potentially reducing the frequency of booster doses required in the future [10].

Maternal Immunisation and Protection of Infants

Maternal immunisation with a tetanus‑diphtheria‑acellular pertussis (Tdap) vaccine is now a cornerstone of whooping‑cough control strategies because it provides passive antibodies to the newborn during the first months of life, when infants are most vulnerable to severe disease and death. The recommended timing is a single Tdap dose during each pregnancy, preferably between 27 and 36 weeks of gestation, allowing optimal transplacental transfer of immunoglobulin G (IgG) antibodies [21], [37].

Rationale and Immunological Basis

When a pregnant individual receives Tdap, the vaccine stimulates a robust systemic humoral response directed against key pertussis antigens—pertussis toxin, filamentous haemagglutinin, pertactin and fimbriae. These antigen‑specific IgG antibodies cross the placenta via the neonatal Fc receptor, reaching concentrations in the neonate that are sufficient to neutralise Bordetella pertussis at the respiratory mucosa. This passive immunity bridges the gap before the infant can complete the primary DTaP series, which begins at 2 months of age. Studies have shown that maternal antibodies can reduce pertussis‑related hospitalisations and mortality in infants younger than 3 months by more than 80 % [21], [37].

Impact on Population‑Level Disease Burden

In countries that have incorporated routine Tdap vaccination during pregnancy, epidemiological surveillance indicates a marked decline in pertussis incidence among infants who are too young to be fully immunised. The reduction is observed not only for symptomatic disease but also for severe outcomes such as intensive‑care admission and death. This effect contributes to overall herd immunity by lowering the number of infectious infants who could otherwise seed community transmission.

Safety Profile in Pregnancy

Safety monitoring programmes have consistently reported that Tdap administered in the third trimester does not increase the risk of adverse pregnancy outcomes, including spontaneous abortion, preterm birth, or congenital anomalies. The reactogenicity profile is comparable to that of routine prenatal vaccines (e.g., influenza), with most reactions limited to mild local soreness, transient low‑grade fever, or short‑lasting fatigue. Serious adverse events, such as anaphylaxis, are exceedingly rare and are managed according to standard vaccine‑related emergency protocols [21].

Programmatic Considerations and Recent Updates

National immunisation programmes have adapted their schedules to include Tdap for every pregnancy, regardless of prior vaccination history. This policy addresses the challenge of waning maternal antibodies from previous immunisations and ensures that each newborn benefits from up‑to‑date protective titres. The World Health Organization’s global guidance also stresses the importance of a coordinated maternal immunisation approach, recommending that countries incorporate the strategy into routine antenatal care services [9].

Ongoing Research and Future Directions

Current research aims to optimize the durability and breadth of infant protection by exploring novel vaccine platforms that could be administered mucosally or in combination with other maternal vaccines. Additionally, studies are evaluating the potential of boosting maternal antibody levels using adjuvanted formulations to further reduce the window of susceptibility in the first two months of life. These investigations are informed by a growing understanding of how secretory IgA and tissue‑resident memory cells contribute to mucosal defence, highlighting the need for vaccines that stimulate both systemic and local immunity [10].

In summary, maternal Tdap immunisation is a highly effective, safe, and globally endorsed strategy that confers critical early protection to infants, supports herd immunity, and aligns with contemporary public‑health objectives to minimize pertussis‑related morbidity and mortality.

Safety Monitoring, Adverse Events and Pharmacovigilance

Robust safety monitoring underpins the public‑health success of pertussis immunisation. Systems that collect, analyse and interpret data on adverse events enable regulators, manufacturers and clinicians to maintain a favourable risk‑benefit analysis while responding rapidly to emerging safety signals.

Post‑marketing surveillance architecture

In the United States, the Vaccine Adverse Event Reporting System (VAERS) provides a national passive surveillance platform that gathers spontaneous reports of any health problem following vaccination, regardless of suspected causality [52]. Parallel active surveillance programmes – such as the CDC’s Enhanced Pertussis Surveillance and targeted cohort studies in Canada – proactively solicit information from health‑care providers, yielding a more complete picture of rare or delayed outcomes [53]. Internationally, the World Health Organization (WHO) coordinates global pharmacovigilance through its Global Advisory Committee on Vaccine Safety, harmonising signal detection criteria across nations [54].

These complementary approaches improve signal detection by combining the breadth of passive reporting with the depth of active case‑finding, allowing identification of safety concerns that would be missed by either method alone.

Common, self‑limiting reactions

Most children experience mild, transient events after receiving an acellular pertussis vaccine. Typical local reactions include pain, redness or swelling at the injection site, while systemic manifestations may comprise low‑grade fever, fussiness, loss of appetite or brief irritability. Such responses generally resolve within 3–7 days and reflect the normal immune response to antigen exposure [55].

In contrast, whole‑cell pertussis vaccines historically induced higher rates of reactogenicity, with fever, prolonged crying, and febrile seizures reported more frequently. Although effective, these systemic side effects contributed to the shift toward acellular formulations in many high‑income settings [20].

Rare but serious adverse events

Serious events are exceedingly uncommon but are rigorously tracked. Anaphylaxis can occur within minutes to a few hours after injection and requires immediate medical management; it is captured by VAERS and national reporting mandates. Historical concerns about neurologic complications, such as seizures or encephalopathy, have largely been disproved for modern acellular products, with contemporary data showing no consistent causal link [57].

Because the whole‑cell vaccine contains multiple bacterial components, it was associated with higher incidences of severe systemic reactions, including rare allergic responses and, historically, reports of convulsions. Modern formulations mitigate these risks through refined purification of antigens such as pertussis toxin, filamentous haemagglutinin, pertactin and fimbrial proteins.

Methodologies for detecting rare, long‑term events

Pharmacovigilance employs several epidemiological tools:

  • Disproportionality analyses of large databases (e.g., VAERS, FDA’s Sentinel System) identify adverse events reported more often than expected.
  • Self‑controlled case series compare incidence periods before and after vaccination within the same individual, reducing confounding by patient‑specific factors.
  • Cohort and case‑control studies linked to electronic health records assess long‑term outcomes such as autoimmune phenomena or sustained neurologic sequelae.

These methods have clarified that waning immunity, rather than vaccine‑induced disease, drives the resurgence of pertussis in older age groups, reinforcing the importance of booster doses for adolescents, adults, and maternal immunisation programmes [37].

Challenges in causality assessment

Distinguishing coincidental health events from those truly caused by vaccination remains a central challenge. The temporal proximity of many illnesses to routine immunisation creates a natural background rate that can be mistaken for a safety signal. Robust causality frameworks—considering biological plausibility, temporal relationship, dose‑response, and consistency with existing evidence—are essential to avoid misattribution that could fuel vaccine hesitancy [59].

Impact on risk‑benefit communication

Transparent communication of both common, expected reactions and the rarity of serious events strengthens public confidence. Emphasising that the protective benefits of pertussis vaccination—preventing severe cough, hospitalisation and death, especially in infants—far exceed the minimal risks helps counteract misinformation and supports high coverage targets needed for herd immunity [16].

Antigenic Variation, Vaccine‑Driven Evolution and Strain Emergence

Pertussis control is increasingly challenged by the ability of Bordetella pertussis to alter its surface antigens and evade immune mechanisms that are induced by current vaccines. This antigenic variation is driven by selective pressure from widespread immunisation, particularly the widespread use of acellular vaccine formulations that contain only a limited set of purified proteins such as pertussis toxin, filamentous haemagglutinin, pertactin and fimbriae. As a result, strains that lack or modify these vaccine‑included antigens can gain a fitness advantage, a phenomenon described as vaccine‑driven evolution.

Mechanisms of Immune Escape

  • Complement evasion – B. pertussis secretes molecules such as the autotransporter protein Vag8 that directly inhibit the complement system, allowing the bacterium to persist even in individuals with partial immunity [61][62]. This evasion reduces the effectiveness of antibodies generated by both whole‑cell vaccine and acellular vaccine programmes.

  • Antigenic drift and loss of pertactin – Genomic surveillance has documented a rapid increase in pertactin‑deficient (Prn⁻) isolates worldwide. Because pertactin is a key antigen in most aP formulations, its loss diminishes antibody recognition and weakens vaccine‑induced protection [63][64]. Mutations in other surface proteins (e.g., filamentous haemagglutinin and fimbriae) further contribute to antigenic drift, reducing the match between circulating strains and vaccine antigens [65].

  • T‑cell polarization differences – Whole‑cell vaccines induce a broad Th1‑polarized cellular immunity that supports durable memory, whereas acellular vaccines skew toward a Th2 profile, generating high antibody titres but weaker cellular memory. This immunological bias facilitates the emergence of strains that escape humoral neutralisation while still being vulnerable to robust Th1‑mediated clearance [12][13].

Consequences for Vaccine Effectiveness

  • Reduced efficacy against infection and transmission – While acellular vaccines retain good short‑term protection against severe disease (≈71‑85 % efficacy), their limited impact on colonisation means that vaccinated individuals can still harbour and spread pertactin‑deficient strains [25]. Whole‑cell vaccines historically provided more sustained protection and better reduction of transmission due to broader antigen exposure [16].

  • Waning immunity and booster needs – The combination of antigenic drift and a Th2‑biased response leads to rapid waning of protective antibody levels, prompting the inclusion of routine booster dose recommendations for adolescents, adults and pregnant people [21]. Boosters aim to raise antibody titres and, in some studies, to re‑engage Th1‑type cellular immunity, thereby partially offsetting the fitness advantage of emerging variants.

Public Health Response and Surveillance

Global health agencies such as the World Health Organization and the Centers for Disease Control and Prevention monitor strain evolution through genomic sequencing networks and vaccine‑effectiveness studies. Early detection of Prn⁻ and other antigenically altered isolates informs updates to vaccine composition and schedules. In addition, research into novel delivery platforms (e.g., mucosal vaccines that elicit secretory IgA and tissue‑resident memory cells) seeks to overcome the limitations of current aP formulations by targeting the pathogen at its site of entry, potentially reducing the selection pressure for escape variants [71].

Next‑Generation Pertussis Vaccines and Novel Delivery Platforms

The resurgence of pertussis despite high coverage with acellular formulations has driven intensive research into next‑generation pertussis vaccines that can provide longer‑lasting protection, reduce bacterial colonisation, and overcome antigenic drift. Modern strategies focus on improving the breadth and durability of the immune response through novel adjuvants, multiepitope designs, and alternative delivery routes that target mucosal immunity.

Expanding Antigenic Coverage and Immune Breadth

Traditional acellular vaccines include purified pertussis toxin, filamentous haemagglutinin, pertactin, and fimbriae. However, Bordetella pertussis continuously undergoes antigenic drift, losing pertactin expression and altering other surface proteins, which diminishes vaccine match [65]. To counter this, researchers are employing computational multiepitope platforms that screen the complete B. pertussis proteome and select conserved peptide regions from multiple antigens, generating broader humoral and cellular targets [73].

Novel Adjuvant Systems for Robust Cellular Immunity

The limited durability of current acellular vaccines stems from their Th2‑biased response, which yields high antibody titres but weak memory T‑cell formation. Potent adjuvants that stimulate Toll‑like receptor 2 (TLR2) have shown promise in preclinical models, markedly enhancing innate activation and driving a more balanced Th1/Th17 profile that mirrors the immunity induced by whole‑cell vaccines [29]. Another promising formulation combines liposomes with the saponin QS‑21, achieving synergistic activation of dendritic cells and fostering both humoral and cellular arms of immunity [75].

Mucosal Delivery to Induce Secretory IgA and Tissue‑Resident Memory Cells

Systemic injection of acellular vaccines mainly generates circulating IgG, which does not prevent B. pertussis attachment to the respiratory epithelium. Intranasal or oral delivery routes directly expose the mucosal immune system, promoting production of secretory IgA (sIgA) that blocks bacterial adhesion and facilitates rapid clearance [10]. Animal studies using intranasal DTaP demonstrated protection against colonisation and cough, underscoring the critical role of sIgA in limiting transmission [10]. Moreover, mucosal vaccination establishes tissue‑resident memory CD4⁺ T cells (TRM) that persist in the airways for years, providing immediate local effector functions upon re‑exposure [25].

Addressing Vaccine‑Driven Evolution

A major driver of pertactin‑deficient strains is the selective pressure exerted by vaccines containing pertactin. By removing single‑antigen reliance and incorporating multiple conserved epitopes, next‑generation formulations aim to reduce this pressure, thereby slowing the emergence of immune‑escape variants [65]. Coupled with adjuvants that generate strong cellular immunity, these vaccines may limit the pathogen’s ability to persist and evolve within the host.

Clinical Development and Regulatory Outlook

Non‑clinical immunogenicity studies now serve as a cornerstone for advancing these platforms, providing early evidence of Th1/Th17 skewing, mucosal sIgA induction, and durable memory B‑cell responses [71]. Regulatory agencies such as the U.S. FDA and the European Medicines Agency require comprehensive mechanistic data—including correlates of protection and adjuvant safety profiles—before progressing to human trials [81]. The integration of robust pre‑clinical data accelerates accelerated‑approval pathways, allowing promising candidates to reach clinical evaluation more rapidly.

Future Directions

The convergence of multiepitope antigen selection, TLR‑based or liposomal adjuvants, and mucosal delivery technologies represents a paradigm shift toward vaccines that not only prevent severe disease but also curb transmission. Ongoing trials are evaluating intranasal formulations with TLR2 agonists, and early phase studies report favorable safety and immunogenicity, supporting the feasibility of these approaches for routine use in infants, adolescents, and pregnant individuals. Successful implementation could finally achieve the long‑sought goal of lifelong, sterilising immunity against pertussis, averting outbreaks across all age groups.

Public Acceptance, Vaccine Hesitancy and Programmatic Challenges

The success of national immunisation programmes against whooping‑cough pathogen depends as much on public acceptance as on the biological effectiveness of the vaccines. Since the early whole‑cell era, concerns about reactogenicity have fueled vaccine hesitancy among parents and adults, creating pockets of under‑immunised populations that enable disease resurgence. Recent data highlight three inter‑related challenges: (1) persisting safety‑related hesitancy, (2) structural barriers to vaccine access, and (3) programmatic constraints that limit delivery of booster doses and maternal immunisation. Together, these factors undermine herd immunity and contribute to the observed increase in pertussis incidence among older children, adolescents and adults. [82] [83]

Safety‑related Hesitancy

Whole‑cell pertussis vaccines (wP) were historically linked to higher rates of fever, febrile seizures and prolonged crying, leading many high‑income countries to replace them with acellular formulations (aP) that have a markedly lower reactogenicity profile. Although aP vaccines are now considered safe, residual concerns persist, especially in communities that recall the older vaccine’s adverse‑event history. Misconceptions that pertussis vaccines cause severe neurological injury continue to circulate despite extensive post‑licensure surveillance showing such events are exceedingly rare. This lingering mistrust can deter parents from completing the primary series or from receiving recommended Tdap booster doses in adolescence and adulthood. [20] [57]

Access Barriers

Even when confidence is adequate, logistical obstacles impede uptake. Vaccine shortages, especially of combination formulations that simplify delivery (e.g., DTaP‑IPV pentavalent), have forced health authorities to seek supplemental supplies, creating temporary gaps in availability. Remote and underserved regions often lack reliable cold‑chain infrastructure, making storage of multi‑dose vials challenging. High out‑of‑pocket costs or lack of insurance further limit access for low‑income families, amplifying socioeconomic disparities in coverage. These access issues are compounded by language barriers and limited health‑literacy resources, which hinder effective communication of vaccine benefits. [86] [87]

Programmatic Constraints

Programmatic suitability—assessing whether a vaccine can be safely and effectively used under local conditions—remains a decisive factor for implementation. Vaccines that require strict cold‑chain storage or multiple injection sites may be unsuitable for settings with limited logistics, prompting reliance on whole‑cell products despite their higher reactogenicity. Additionally, the need for timely adolescent and adult Tdap booster administration strains existing delivery platforms, which are often centered on childhood schedules. Maternal immunisation programmes, recommended to protect newborns, require coordinated prenatal care visits; gaps in antenatal service uptake therefore translate into missed opportunities for pertussis protection. Recent policy shifts in the United Kingdom, which replaced one pregnancy‑dose product with another due to supply considerations, illustrate how vaccine availability can directly affect program continuity. [88] [89]

Impact on Public Health Outcomes

The combined effect of hesitancy, access gaps and programmatic limits manifests as persistent pockets of low coverage that facilitate transmission, particularly to infants who are most vulnerable to severe disease and death. Outbreak investigations consistently link these pockets to under‑vaccinated adolescents and adults, whose waning immunity permits bacterial colonisation and spread. Consequently, achieving the estimated 80 %–90 % herd‑immunity threshold for pertussis requires not only high primary‑series uptake but also sustained booster coverage across the lifespan. Failure to address the identified challenges risks a cycle of resurgence, despite the overall historical success of pertussis vaccination in reducing global morbidity and mortality. [11] [41]

Strategies to Overcome Barriers

  • Targeted education campaigns that directly confront safety myths, using transparent data from VAERS and WHO safety evaluations.
  • Improved supply chain management for combination vaccines, including regional stockpiles and flexible procurement agreements to prevent shortages.
  • Integration of pertussis boosters into existing adult health visits (e.g., chronic‑disease clinics, pharmacy‑based immunisation services) to reduce missed opportunities.
  • Strengthening maternal immunisation pathways by linking pertussis vaccination to routine antenatal appointments and offering it in community‑based maternity centres.
  • Adapting vaccine formulations to local programmatic needs, such as developing thermostable aP products that relax cold‑chain requirements, thereby expanding reach in low‑resource settings.

Addressing these multidimensional challenges is essential for sustaining the gains achieved since the early 20th‑century introduction of pertussis vaccines and for moving toward durable, population‑wide control of whooping cough.

References